Press release article from our research archive:

FDA Maintains Clinical Hold on Alteon's ED Study of Alagebrium.

PARSIPPANY, N.J., Sept. 30 /PRNewswire-FirstCall/ -- Alteon Inc. announced today that it has been notified by the U.S. Food & Drug Administration's (FDA) Reproductive and Urologic Drug Products Division that it is maintaining the clinical hold previously placed on the Company's Phase 2a study of alagebrium in diabetic patients with erectile dysfunction.

In June, the Company announced that it had submitted preclinical toxicity data on alagebrium to two divisions of the FDA's Center for Drug Evaluation and Research (CDER), specifically the Division of Cardio-Renal Drug Products and the Division of Reproductive and Urologic Drug Products. The preclinical toxicity data were ...

Related newspaper, magazine, and journal articles:

See all results. Or, try our Advanced Search.

Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 60 million articles! Access over 3,500 publications with a FREE trial!